SCHEMBL4027586

SCHEMBL4027586

CC(=O)c1ccc2noc(-c3ccc(Cl)cc3)c2c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 11/20 1.00
SMN1; SMN2 Q16637 4/20 1.00
KDM4E B2RXH2 5/20 0.78
L3MBTL1 Q9Y468 2/20 0.78
MEN1 O00255 5/20 0.76
KMT2A Q03164 5/20 0.76
NPC1 O15118 2/20 0.72
GAA P10253 1/20 0.64
HTT P42858 1/20 0.64
IP6K1 Q92551 8/20 0.61
IP6K3 Q96PC2 7/20 0.61
IP6K2 Q9UHH9 7/20 0.61
POLB P06746 2/20 0.61
RAB9A P51151 1/20 0.61
MAPT P10636 3/20 0.59
GFER P55789 1/20 0.59
HSD17B10 Q99714 2/20 0.58
TP53 P04637 1/20 0.58
LMNA P02545 1/20 0.57
TSHR P16473 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4025676 0.86 ALDH1A1 (0.78) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1
SCHEMBL4033499 0.86 MEN1 (1.00) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1
SCHEMBL4027834 0.86 ALDH1A1 (1.00) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1
SCHEMBL4027637 0.80 POLB (0.81) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1
SCHEMBL8959133 0.80 ALDH1A1 (0.81) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1
SCHEMBL4024961 0.79 IP6K1 (0.67) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1
SCHEMBL4028729 0.79 IP6K1 (0.81) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1
SCHEMBL25991293 0.78 IP6K1 (0.83) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL12330213 0.78 ALDH1A1 (0.63) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1
SCHEMBL5514440 0.76 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2KDM4EL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1399440-B1 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2009-06-03 EP disclosed
US-20050228005-A1 Protein kinase inhibitors and uses thereof MOON YOUNG C 2005-10-13 US disclosed
US-6825190-B2 4-(1,2- OR 2,1-BENZOXAZOL-5-YL)-2-AMINOPYRIMIDINES VERTEX PHARMACEUTICALS INCORPORATED 2004-11-30 US disclosed
WO-2002102800-A9 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS VERTEX PHARMA (US) 2004-05-06 WO disclosed
EP-1399440-A1 5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS Vertex Pharmaceuticals Incorporated (US) 2004-03-24 EP disclosed
US-20040009996-A1 Protein kinase inhibitors and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2004-01-15 US disclosed
WO-2002102800-A1 5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-12-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040009996-A1 Protein kinase inhibitors and uses thereof GSK3A, GSK3B, JAK3 ALDH1A1 1993/4885SMN1; SMN2 4313/4885KDM4E 1389/4885
US-20050228005-A1 Protein kinase inhibitors and uses thereof GSK3A, JAK3, GSK3B ALDH1A1 2590/4885SMN1; SMN2 4358/4885KDM4E 1497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.